Eli Lilly raises sales target again after strong quarter

Business with Mounjaro and Zepbound

The high demand for these medications has made Eli Lilly one of the most valuable companies in the healthcare sector in recent months. The group is investing massively in the expansion of its production capacities in order to avoid supply bottlenecks and to open up new markets.

At the same time, competition is increasing. The Danish competitor Novo Nordisk produces a competing product with Wegovy and is likewise expanding its offering worldwide. Both companies are attempting to grow the market with new dosage forms and studies.

Growing competition and criticism

Analysts, however, do not view the trend uncritically. They point to possible side effects, the need for long-term medical supervision, and the fact that the therapy remains expensive for many patients in the long term.

Despite these objections, Eli Lilly continues to expect growing interest. On a conference call, management reaffirmed the plan to noticeably increase delivery volumes in the coming quarters and to invest in additional active ingredient variants. The group aims to reach patients outside its existing main markets as well.

Equipment suppliers in the environment also benefit

In parallel, the entire industry of semiconductor and network equipment suppliers is benefiting. Arista Networks, for example, is recording high orders for network solutions in data centers used for AI applications – including those supporting pharmaceutical research processes. "Arista Networks profitiert von der hohen Nachfrage nach Netzwerklösungen für KI-Rechenzentren," it says in this regard.

Observers interpret the renewed upward revision of the forecast as a signal that the market for weight-loss medications in the United States and Europe continues to grow. Should the pace continue, Eli Lilly could further consolidate its position as the global market leader in the area of so-called GLP-1 products in the coming years.